ANGPT2 and neoplasm: However, it will be meaningful to mention that vanucizumab (ANG2-VEGFA Cross Mab, Roche) failed to show improved clinical outcomes in metastatic colorectal cancer in comparison with bevacizumab [53], although ANG2-VEGFA Cross Mab showed a strong inhibition of angiogenesis and tumor regression in animal tumor model mice [54].